Export

Pyrazinamide
Essential medicine status
Section:
6. Anti-infective medicines 6.2. Antibacterials 6.2.5. Antituberculosis medicines
ATC codes: J04AK01
EMLc
Indication
Tuberculosis ICD11 code: 1B4Z
INN
Pyrazinamide
Medicine type
Chemical agent
List type
Core
Additional notes
WHO recommends and endorses the use of fixed-dose combinations and the development of appropriate new fixed-dose combinations, including modified dosage forms, non-refrigerated products and paediatric dosage forms of assured pharmaceutical quality.
Formulations
Oral > Solid: 400 mg ; 150 mg tablet (dispersible) ; 500 mg
EML status history
First added in 1982 (TRS 685)
Changed in 1997 (TRS 882)
Changed in 2007 (TRS 946)
Changed in 2007 (TRS 950)
Changed in 2021 (TRS 1035)
Changed in 2023 (TRS 1049)
Sex
All
Age
Also recommended for children
Therapeutic alternatives
The recommendation is for this specific medicine
Patent information
Patents have expired in most jurisdictions
Wikipedia
Pyrazinamide
DrugBank
Pyrazinamide
Summary of evidence and Expert Committee recommendations
The Committee recommended deletion from the EML and/or EMLc of various formulations and strengths of amikacin (injection: 100 mg/2 mL (as sulfate) in 2 mL vial), ethambutol (Oral liquid: 25 mg/mL), ethionamide (tablet: 125 mg), isoniazid (oral liquid: 50 mg/5 mL), linezolid (powder for oral liquid: 100 mg/5 mL), p-aminosalicylic acid (granules: 4 g in sachet) and pyrazinamide (oral liquid: 30 mg/mL), noting that they are not optimal formulations and strengths for tuberculosis treatment.